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Background: The WHO recommends supervised administration of sulphadoxine-pyrimethamine (SP) as intermittent
preventive treatment for malaria (IPTp) during pregnancy. Logistical constraints have however favoured unsupervised
intake of SP-IPTp, casting doubts whether recent guidelines requiring more frequent intake can be effectively
implemented. To propose strategies for enhancing compliance under limited supervision, this study sought to
identify pregnant women’s knowledge and practices gaps as well as determine predictors of compliance with
SP-IPTp, given under limited supervision.
Methods: A cross-sectional study of 700 women used exit interviews at an urban clinic in Uganda to obtain a
descriptive summary of demographic and obstetric characteristics, including knowledge, practice and experiences
with SP. Predictors of compliance with SP intake instructions were explored using logistic regression.
Results: Median age of respondents was 25 (IQR 22–28) and median parity was two (IQR one to three) while
median number of antenatal clinic (ANC) visits was 3.0 (IQR three to four). Most women had completed primary
(36%) or ordinary secondary education (25.6%) while 16.1% had not completed primary education. Awareness
about SP was high (99.4%) although correct knowledge regarding its use in pregnancy was low (57%), with 15.4%
thinking it was used to treat malaria and 26.7% lacking any idea about its use. Correct knowledge on SP use
during pregnancy significantly predicted compliance with SP-IPTp instructions (OR 1.98, C.I. 1.12-3.55), while age,
education level, parity, number of ANC visits, or history of unwanted effects with SP did not. SP was mostly
accessed from hospitals (64.4%) followed by private clinics (16.9%) both for preventive and treatment purposes.
SP was considered safe by most women, who were willing to take it again in future, without supervision.
Conclusion: Despite high awareness, knowledge of SP as an intervention for malaria prevention in pregnancy was
low. Correct knowledge on use of SP predicted compliance with SP-IPTp intake instructions. Focused malaria-related
education during ANC visits may improve compliance with SP intake amidst limited supervision.
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Malaria continues to be an important public health
problem in Africa where it contributes significantly to
adverse pregnancy outcomes [1]. Over 30 million preg-
nancies at risk of malaria occur in Africa each year [1].
Uganda, having the third highest fertility rate in the
world [2], bears a considerable proportion of the malaria
burden in pregnancy. Intermittent preventive treatment
of malaria during pregnancy (IPTp), with sulphadoxine-
pyrimethamine (SP) is a key component of the WHO’s
strategy to mitigate the adverse impact of malaria on
pregnancies in Africa [3]. Despite the wide adoption of
IPTp as policy in malaria-endemic countries, there has
been a global debate as to whether SP is still the most
appropriate drug [4,5]. Critical among the concerns has
been the rising tide of SP resistance across Africa [6-8].
However, because the efficacy requirement for preven-
tion is less than that for treatment of clinical malaria,
technical reviews have consistently shown that SP-IPTp
is still beneficial, even where prevalence of resistance is
considerably high [9-11].
Alternative delivery mechanisms for IPTp aimed at
reaching as many pregnant women as possible have been
another area of debate [12-14]. The WHO recommends
that IPTp be given through antenatal clinic (ANC)
platforms to all pregnant women under the direct super-
vision of a health worker [3]. However, reports from
various African countries suggest that this has been par-
ticularly difficult to achieve, mainly because of logistical
constraints imposed by high client numbers [15-19]. As
such, unsupervised intake of SP-IPTp is the reality in
many settings, a scenario that requires the full cooper-
ation of pregnant women if implementation of this policy
is to succeed.
Even though multiple factors such as perceived risk-
benefits, provider-client relationship, previous drug ex-
periences among others, are known to influence compli-
ance with oral medication [20,21], pregnancy comes
with additional challenges. For instance, physiological
changes create a general aversion to oral medication
[22]. This is likely to reduce compliance especially in cir-
cumstances where intake is unsupervised. Furthermore,
pregnant women tend to over-estimate the risks associ-
ated with drug use during pregnancy [23]. Such fears
have been particularly documented with SP in Nigeria
[15] and Uganda [24]. It is likely that such considerations
underlie reports that some pregnant women receive but
do not take IPTp medication [15,25]. Therefore, imple-
mentation of the revised WHO policy [26], requiring more
frequent administration of SP-IPTp is likely to pose a for-
midable challenge under the current circumstances. If the
full impact of this revision is to be realized, there is need
for specific interventions aimed at improving pregnant
women’s willingness to take SP under limited supervision.In order to gain insight and propose mitigation strategies
against the above challenges, this study sought to identify
knowledge and practice gaps associated with SP-IPTp
among pregnant women in Uganda. Specifically, the study
explored a range of factors so as to determine predictors
of compliance with SP-IPTp under the current circum-
stances. Lastly, the study describes pregnant women’s per-
ceived adverse experiences with SP and examines their
willingness to take it again under limited supervision.
Methods
Study design
This was a cross-sectional study encompassing both de-
scriptive and analytical aspects. Data for this study were
collected as part of a wider cross-sectional study whose
objectives included exploration of pregnant women’s
knowledge and experiences with malaria during preg-
nancy, determination of their anti-malarial drug sources
and use patterns during pregnancy, exploration of their
knowledge and practices regarding SP-IPTp and descrip-
tion of their previous experiences with SP-IPTp. Exit in-
terviews were used to collect data from pregnant women
attending antenatal care at an urban hospital in Uganda.
Even though data for the above objectives were all col-
lected concurrently, using the same tool and from the
same sample population, this paper addresses only the
last two objectives.
Study site and study population
Mulago National Referral and Teaching Hospital is a
1,500-bed complex located in Kampala, the capital and
commercial centre of Uganda. It offers a wide range of
specialized care and runs free outpatient clinics on
weekdays. Most outpatients come from the urban and
peri-urban communities of Kampala and the neighbour-
ing districts of Mukono and Wakiso. These areas are
mainly inhabited by the ethnic Bantu, particularly the
Baganda. Over time however, other Ugandan ethnic
communities have settled here constituting a significant
minority. Most outpatients visiting the hospital tend to
be low- and middle-income earners who prefer to utilize
the free services offered at the hospital. Records show
that over 1,000 outpatients are seen daily, with approxi-
mately 20% of these being pregnant women seeking
antenatal care at the hospital’s two ANC clinics. All
women initially present to the general ANC located at
Old Mulago. This clinic is run by a team of experienced
midwives and offers a standard package of routine ante-
natal care services. If the opinion of an obstetrician is
required or the pregnancy is considered of a high-risk
nature, women are referred to the New Mulago ANC.
Since all women are initially seen at the general ANC
clinic, only attendees from this clinic were approached
for the study. The current government policy on IPTp is
Odongo et al. Malaria Journal 2014, 13:399 Page 3 of 8
http://www.malariajournal.com/content/13/1/399that all HIV-negative women should get at least two
doses of SP-IPTp during each pregnancy, while HIV-
positive women are initiated on daily co-trimoxazole
prophylaxis instead of SP-IPTp. For the management of
clinical malaria during pregnancy, the policy recom-
mends use of quinine in the first trimester of gestation
and ACT or quinine in second and third trimesters [27].
Antenatal clinic setting
The general ANC clinic runs from 08:00 to 16:00 hours
on all weekdays and is attended by an average of ninety
pregnant women on each day. All services (including
medications) are offered free to all patients. Daily activ-
ities begin with an hour-long group talk offered to all
women attending on that day, regardless of age, educa-
tion level, parity, number of previous visits or gestational
age category. This session is conducted by the clinic in-
charge who ensures that all women visiting the clinic at-
tend. Issues covered include pregnancy-related health
education, counselling on pregnancy and emergency pre-
paredness, nutrition, hygiene, birth plan, post-partum
care, breast feeding, prevention of sexually transmitted
infections and family planning. During this session,
women are encouraged to ask questions. After the group
talk, women are directed into private consultation rooms
where they are offered additional services which include a
standard antenatal examination, voluntary counselling and
testing for HIV and syphilis, and tetanus immunization.
Depending on the case, a woman may be referred or sent
to the laboratory or ultrasound room for further investiga-
tion. For those with normal pregnancies, prescriptions for
SP-IPTp, haematinics or anti-helminthic tablets may be
given, whichever is due. Prescriptions for other minor
intercurrent illnesses may also be given. The date for their
next visit is given and women are discharged via the clinic
pharmacy where their medication is dispensed.
Sample size determination
A minimum sample size of 385 was estimated to answer
the current objectives using the formula of Cochran [28]
based on the following parameter assumptions; a 5% level
of precision (sampling error) and a standard normal devi-
ate (Zα) of 1.96 (for a confidence level of 95%). A max-
imum degree of variability (0.5) in compliance with IPTp
intake instructions was assumed as there was paucity of
data on compliance with SP-IPTp from this population, or
any other similar population. As this study was part of a
larger study on malaria and anti-malarial drug use among
pregnant women, a final sample size of 700 computed to
cover the other objectives was used.
Research instrument
A structured questionnaire, mainly consisting of close-
ended questions was developed based on themes containedin the malaria in pregnancy treatment and prevention
models proposed by Ribera et al. [29] (see Additional file 1).
The questionnaire included questions on sociodemographic
and obstetric characteristics relevant to study objectives.
Areas of inquiry identifying SP knowledge gaps included
whether women had ever heard about SP, whether they
knew about its role as given during pregnancy and whether
they recalled the health workers’ dosing instructions. Areas
of inquiry identifying practice gaps included history of SP
use during pregnancy, the source of SP, reasons for which
SP was used (if positive) during pregnancy, number of
tablets received, and number of tablets actually taken.
Lastly, a section on unwanted effects that women attributed
to SP use, as well as their willingness to use SP again in
future was included. Prior to actual data collection, the
questionnaire was pre-tested on 50 pregnant women from
the same clinic. This exercise allowed the research team to
standardize questions and cater for all possible responses so
as to ensure internal validity. In addition, potential bottle-
necks to smooth conduct of both clinic and study activities
were identified and streamlined.
Recruitment and data collection
Recruitment and data collection for the entire study was
done over three weeks between 5th and 23rd August
2013. Pregnant women leaving the consultation rooms
were consecutively approached and invited to take part in
the study. This strategy served to exclude HIV-positive
women who upon diagnosis, are normally referred to the
New Mulago ANC clinic (located on another building).
All other potential participants regardless of gestational
age were eligible for recruitment. Information about the
study was explained to each woman before they gave oral
consent to participate. Three female students of nursing
were trained and assisted in this exercise. On each
clinic day, data collection begun at 09:00 and ended at
13:00 hours. Each research assistant administered the
questionnaire to an average of 15 pregnant women per
day, with each interview lasting between ten to fifteen
minutes. The interviewers were free to ask any other
specific questions in order to satisfy themselves that SP
was not being confused with other routine ANC medi-
cations. Communication was either in English or a
local vernacular language (whichever was convenient
for individual women). Whilst in the clinic, one of the
investigators scrutinized all completed questionnaires
to ensure correctness and completeness of records be-
fore they were filed.
Data management and statistical analysis
Data were coded, double-entered and validated in
EpiData® [30] from where it was exported to R statis-
tical computing software [31] for analysis. Descriptive
statistics were used to summarize sociodemographic,
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ence data. Compliance with SP-IPTp intake instructions
was defined as participants who reported receiving
three tablets of SP and took all three tablets at once.
This was the main outcome variable in this study. Other
variables such as participant age, education level, parity,
number of ANC visits in most recent pregnancy and
correct knowledge on the role of SP (as used during
pregnancy) were investigated as predictors of compli-
ance with SP intake instructions. As regards knowledge
on the role of SP, one was considered to have correct
knowledge if they said SP was used to prevent malaria.
Thus, for purposes of analysis, there were only two cat-
egories for this variable. Multicollinearity was examined
between all variables by calculating the variable inflation
factor (VIF) for each predictor variable. Binomial
logistic regression was then used to investigate each,
beginning with univariate analysis. Odds ratios were
computed for each variable with statistical significance
set at p ≤0.05 at the 95% confidence level. In order to
avoid confounding bias in effect estimates arising when
bivariate selection is used for inclusion of variables in
multivariate models [32], all variables regardless of sig-
nificance, were included in the full multivariate model.
The robustness of the final model was validated by non-
parametric bootstrapping, with 1,000 new datasets ran-
domly generated from the original dataset.Ethical considerations
In order to avoid the possible negative influence of
written consent on rapport between interviewer and
respondent, women were required to give only oral
informed consent. In any case, the study was also
deemed to pose minimal risks to participants. Confi-
dentiality was maintained by ensuring one-on-one
interviews in private, well-lit rooms. Numeric identifi-
cation codes were used in order to conceal individual
identities and all records were securely handled by
study staff. The study protocol was reviewed and ap-
proved by the Mulago Hospital Research and Ethics
Committee (ref MREC number 397) and permission to
conduct the study was granted by the Uganda National
Council for Science and Technology (UNCST).Results
General characteristics of pregnant women surveyed
All women approached for the study consented to par-
ticipate. The median age (and IQR) was 25.0 (22–28)
years with a minimum and maximum of 16 and 43 years,
respectively. Median gestational age (and IQR) was 24.0
(20–32) weeks with a minimum and maximum of four
and 36 weeks, respectively. Other characteristics of the
women surveyed are presented in Table 1.Knowledge associated with SP use during pregnancy
Nearly all respondents (99.4%) had heard about SP prior
to the interview. Regarding knowledge on the role of SP
as used during pregnancy, 57% mentioned prevention of
malaria in mother or unborn baby while 15.4% thought
it was used to treat malaria. About 26% and 0.9% re-
spectively, did not know its indication or cited other
reasons not related to malaria (Table 1). Regarding
knowledge on the dosing of SP as per health workers’ in-
structions, 86.5% of respondents mentioned the correct
dosing instructions i.e. three tablets all taken at once.
Practices associated with SP use during pregnancy
Most respondents (89.9%) had used SP during preg-
nancy with 63.9% having used it in their current preg-
nancy. Most respondents (64.4%) had accessed SP
from a hospital followed by a private clinic (16.9%) or
other public health facility (10.2%). When asked to
recall why they had used SP during pregnancy, 54.1%
mentioned that it was offered on a routine ANC visit
about which they had no particular complaint (or
symptom) related to malaria. Twenty-six per cent re-
ported receiving SP because they had complained of
malaria symptoms while 11.3% received it on separate
occasions both as routine ANC medication as well as
when they had confirmed episodes of malaria during
pregnancy. Approximately 9% could not recall why
they were given SP during pregnancy. When asked to
mention the number of SP tablets they had received
along with the health workers’ dosing instructions,
86.5% reported that they were given three tablets
with instructions to take all at once. This same pro-
portion of women reported using SP in the manner
instructed thus meeting the criteria that defined
compliance in this study. Other respondents 4.6 and
2.5% reported receiving more than three or less than
three tablets, respectively, to be taken at various
times. Forty women (6.4%) could not recall the num-
ber of tablets received.
Predictors of compliance with SP-IPTp intake instructions
All predictor variables had VIF values less than 1.86
(R2 < 0.46) suggesting limited collinearity between vari-
ables. This allowed for all to be independently entered
into the multivariate model without fear of loss of preci-
sion in effect estimates. Logistic regression showed
that participant age, education level, number of ANC
visits in previous pregnancy and correct knowledge on
SP-IPTp were significantly associated with compliance
with SP intake instructions when independently inves-
tigated (Table 2). However, in the multivariate model,
only correct knowledge on SP use remained statisti-
cally significant with effect estimates showing that it
offered approximately two-fold increase in compliance
Table 1 General characteristics of pregnant women





Parity (number of previous pregnancies ≥28 weeks)
First pregnancy 148 21.1
Second pregnancy 173 24.7
Third or more pregnancies 379 54.2
Number of ANC visits in last pregnancy (n = 552)*
None 32 5.8
One or two visits 90 16.3
Three visits 161 29.2
Four or more visits 269 48.7
Education level completed
None or never completed primary 113 16.1
Primary education 252 36.0
Ordinary level education 179 25.6
Advanced level education 87 12.4
Tertiary education 69 9.9
Knowledge on SP-IPTp use during pregnancy
Prevent malaria in mother
(or unborn baby)
399 57.0
Treatment of malaria 109 15.4
Do not know 187 26.7
Other response 6 0.9
Experienced SP-IPTp unwanted





Severe (skin reaction, abdominal pain,
general weakness)
92 14.6
*Data excludes primigravidae, **data from only previous users of SP-IPTp.
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sults of non-parametric bootstrap analysis showed
minimal bias of less than 10% for all model estimates.
All estimates also lay within the bias-corrected 95%
confidence intervals (Table 3).Table 2 Model outputs for predictors of compliance with inst




Number of ANC visits 1.201
Correct knowledge on SP-IPTp use 2.492
Experience of SP unwanted effects 1.477
Hosmer and Lemeshow goodness of fit (GOF) test: χ2 = 4.8907, df =8, p-value =0.76
*Parity = Number of previous pregnancies >28 weeks, OR = Odds ratio, CI = ConfidePerceived unwanted effects of SP-IPTp and willingness to
take it again
Overall, 68.7% of pregnant women felt that SP was safe
because they did not experience any bad effects follow-
ing intake. However, up to 31.3% experienced some
form of unwanted effect, which they attributed to SP.
The most common effects mentioned were nausea and
vomiting (7.3%) and general body weakness (7.0%).
Other effects mentioned were headache or dizziness
(5.9%) and abdominal pain or diarrhoea (1.4%). Few par-
ticipants (5.9%) reported more than one unwanted effect.
Occurrence of allergic-type reactions, such as skin erup-
tions or fever-like symptoms, were reported by 0.3 and
0.9% of women, respectively. When asked whether they
would take SP again given their previous experiences,
most women (92.7%) were willing to take it again.
Among the few (n = 57) who responded negatively, forty
seven cited fear of injury to themselves while ten cited
fear of injury to their unborn baby.
Discussion
This study sought to identify knowledge and practice
gaps associated with SP-IPTp among an urban popula-
tion of pregnant women attending ANC in Uganda. Des-
pite high awareness and access to SP during pregnancy,
correct knowledge about its use in pregnancy was less
than adequate. A high proportion of women (43%) either
did not know the role of SP or thought it was still used
for malaria treatment. This is worrisome coming from
a group of pregnant women who attend ANC, because
it raises doubt whether these women can willingly take
SP (without supervision) in the absence of malaria
symptoms.
Because antenatal care platforms are supposed to pro-
vide access to a wide range of pregnancy friendly interven-
tions, optimum ANC attendance is probably the most
important decision pregnant women and their partners
make. ANC attendance in this population was suboptimal
with less than half of women making the minimum rec-
ommended four visits in their most recent pregnancy.
Previous studies in Uganda have reported similarly low
figures: 34% in Jinja [19] and 37.1% in Luweero [33]ructions for SP-IPTp intake









Table 3 Model validation results from bootstrap analysis using 1000 randomly generated datasets
Original log odds Bias (%) Std. error Bias corrected and accelerated 95% CI
Intercept –0.998 –6.561 1.059 (–3.119 – 0.950)
Participant age 0.052 0.265 0.048 (–0.041 – 0.141)
Education level 0.243 0.871 0.132 (–0.022 – 0.494)
Parity 0.049 0.529 0.141 (–0.229 – 0.333)
No. of ANC visits 0.106 0.035 0.101 (–0.108 – 0.293)
Correct knowledge on SP 0.683 0.748 0.303 (0.067 – 1.278)
Experience of SP unwanted effects 0.201 3.397 0.363 (–0.506 – 0.881)
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national average of 25% as per the most recent Demo-
graphic and Health Survey report [34]. Across sub-Saharan
Africa, wide variation in ANC attendance patterns has
been noted. A recent review on this subject estimated that
71% of women attend ANC at least once, with only 44%
making four or more visits [35]. Reasons for non-ANC
attendance have been identified in several studies [36,37]
and include issues relating to ignorance, access (availabil-
ity, costs), concerns about religious or cultural violations,
and the perception of having a normal pregnancy
(especially common among multiparous women). In some
instances, non-ANC attendance was attributed to a per-
ceived lack of enforcement by relevant local authorities.
Studies also show that women who make fewer ANC
visits have the least chance of accessing pregnancy friendly
interventions [37,38]. Moreover, such few attendances
tend to occur later in pregnancy, thus particularly affect-
ing preventive interventions like malaria-related health
education which is normally begun in early pregnancy.
Lack of knowledge about when to start ANC visits has
been identified as the most critical reason associated
with late index ANC attendance at Mulago hospital [39]
and this may account for some of the SP knowledge
gaps identified in this study.
Over one third of pregnant women received SP follow-
ing presentation with malaria symptoms. This is worri-
some as it suggests that some health workers continue
to prescribe (or dispense) SP for treatment of symptom-
atic malaria among pregnant women. SP no longer has
the efficacy required for treating clinical malaria. Its use
instead of quinine or ACT, therefore, increases the risk
of adverse pregnancy outcomes such as abortions due to
ineffectively treated malaria. These findings are not en-
tirely new in Uganda where recent studies from Jinja
[40] and Mukono [41] districts have reported a 37 and
48% use of SP among febrile pregnant women, respect-
ively. Until now, such rampant misuse of SP was thought
to be unique to rural populations. However, this report
suggests that the pattern may not be different among
urban women. Elsewhere, a recent study in Nigeriarevealed that chloroquine and SP were the most com-
mon anti-malarial medicines used among rural preg-
nant women [16]. Considering that hospitals, followed
by private clinics, were the most common sources of
SP in this study, these findings indicate a high degree of
non-adherence to treatment guidelines among health
workers. This trend requires an urgent check as it carries
serious implications for the well-being of pregnancies
afflicted by malaria in Uganda.
Pregnant women reported a high degree of compliance
with SP instructions (86.5%) when received as IPTp.
Similarly, high compliance rates (77.4%) were reported
by Akinleye et al. among rural Nigerian women [15].
The high compliance rate in this study and the fact that
nearly all women were willing to take SP again in future,
suggests that SP is perceived as a relatively safe drug.
This is contrary to earlier reports in which SP was per-
ceived as ‘too strong’, thereby likely to weaken pregnant
women and cause abortions or foetal abnormalities [24].
These findings are in line with earlier suggestions by
Sangare et al. that when offered SP-IPTp, pregnant
women will accept and use it [19]. In this study, correct
knowledge on SP-IPTp was found to be a significant
predictor of compliance with intake instructions. This is
consistent with findings from one Nigerian study that
suggested that knowledge about malaria prophylaxis in
pregnancy predicted IPTp utilization among rural
women [16]. Findings from the two studies underscore
the notion that awareness of the health benefits of an
intervention will promote its uptake, at least during
pregnancy. The importance of knowledge and awareness
campaigns aimed at promoting positive health practices
was therefore highlighted by this study.
It was reasonable to assume that pregnancy presented
an opportunity to learn about SP-IPTp or other pregnancy-
related health information. This would be especially true
among women who attended ANC because of the in-
creased likelihood to interact with appropriate information
sources. Since the majority of women in this study had ex-
perienced at least one previous pregnancy, for which a me-
dian of three ANC visits were made, it was anticipated that
Odongo et al. Malaria Journal 2014, 13:399 Page 7 of 8
http://www.malariajournal.com/content/13/1/399number of ANC visits (in a previous pregnancy) would
positively predict reported compliance with IPTp instruc-
tions. This was however not true and may point towards a
deficiency in malaria-related health education as normally
given during ANC visits. Alternatively, malaria-related
health messages (if any) presented during ANC visits may
be inappropriately tailored to pregnant women’s needs. In
addition, this observation may be a manifestation of late
ANC attendance as earlier observed in this discussion.
This report may be considered unique in attempting
to present actual users’ experiences and perceptions on
SP safety, in contrast to most studies that have used pro-
vider perspectives. Overall, its findings are consistent
with a previous review upholding the safety of SP in
pregnancy [42]. Pregnant women in this population may
therefore have a low risk perception towards SP consid-
ering the high compliance rate and willingness to use it
again in future. Cases of non-compliance with SP intake
(if any) are likely to arise due to factors such as physio-
logical aversion to oral medication or a perceived lack of
benefit (from SP) owing to limited knowledge as elabo-
rated above.
A key limitation of this study was the exclusive reli-
ance on respondents’ verbal reports as a measure of out-
come variable (i.e., compliance with SP-IPTp intake
instructions). This was subject to social desirability bias
as respondents’ answers may have reflected what they
believed the interviewer would find acceptable, not ne-
cessarily the fact of SP intake. As such, it is possible that
some level of inaccuracy in outcome measurement
occurred. Even though this was anticipated, little could be
done to control for it within a cross-sectional study design.
Furthermore, these findings may not be generalizable to
all Ugandan women, particularly those who do not attend
ANC. However, such persons cannot access SP-IPTp
within the current delivery platform, hence their views are
of limited consequence on the current implementation
challenges. However, the robustness shown by bootstrap
analysis provides a basis for generalization of study find-
ings to ANC-attending pregnant women living in both
urban and non-urban settings within Uganda. These find-
ings may also apply elsewhere in developing countries
with similar sociodemographic profiles and health system
challenges. Lastly, the use of exit interviews precluded the
possibility of obtaining greater insights into SP-IPTp
knowledge and practices as this would have required the
addition of focus group discussions. Nevertheless, the
current study provides useful insights into important
knowledge and practice gaps associated with SP use dur-
ing pregnancy.
Conclusion
Despite high awareness of SP, knowledge on the ration-
ale of its use during pregnancy was less than adequate.Correct knowledge on the role of SP during pregnancy
predicted compliance with SP-IPTp intake instructions.
SP was perceived as a relatively safe drug and women
were willing to take it again without supervision. For as
long as unsupervised intake of SP-IPTp remains routine,
providers should endeavour to inform and educate preg-
nant women on the rationale of this intervention. Infor-
mation should emphasize the importance and benefits of
compliance with SP-IPTp.
Additional file
Additional file 1: Malaria and anti-malarial drug use patterns
among pregnant women attending Mulago Referral Hospital,
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